BTAI BioXcel Therapeutics

BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update

BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update

Conference Call scheduled to discuss results on August 6, 2019 at 8:30 AM EDT

NEW HAVEN, Conn., July 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), today announced that the Company is scheduled to release its second quarter and half year 2019 financial results on Tuesday, August 6, 2019. BTI will also hold a conference call on Tuesday, August 6, 2019 at 8:30 AM Eastern Time to discuss the financial results and provide a business update. BTI is a clinical-stage biopharmaceutical development company that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.

Conference Call & Webcast Details

Tuesday, August 6, 2019, 8:30 AM Eastern Time

Domestic:                    1-800-239-9838

International:               1-323-994-2093

Conference ID:            2198753

Webcast:                    

Replay

Domestic:                    1-844-512-2921

International:               1-412-317-6671

Conference ID:            2198753

*Replay available through September 6, 2019

About BioXcel Therapeutics, Inc. (BTI):

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit 

Contact Information:

The Ruth Group for BTI:

Janhavi Mohite

646-536-7026

EN
30/07/2019

Underlying

BTAIBioXcel Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioXcel Therapeutics

 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medi...

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia Large patient population affected by Alzheimer’s agitation, with approximately ~100 million annual episodes1 KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST NEW HAVEN, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BT...

February 19, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Completes Market Opportunity Assessment and Advan...

BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting Third party commercial assessment shows larger than expected potential total addressable market for IGALMI® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary coverage NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced th...

February 12, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S....

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI® Submission timeline supports potential approval of IGALMI® label expansion as early as year-end 2026 NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transform...

January 20, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of ...

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative med...

January 12, 2026 1 EN
 PRESS RELEASE
Free
BTAI BioXcel Therape...

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Ap...

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month ...

January 7, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch